CN Stock MarketDetailed Quotes
002773 Chengdu Kanghong Pharmaceutical Group
- 19.35
- +0.29+1.52%
Not Open Jan 6 15:00 CST
17.80BMarket Cap14.92P/E (TTM)
19.73High19.09Low56.94KlotVolume19.09Open19.06Pre Close110.51MTurnover0.83%Turnover Ratio17.03P/E (Static)919.78MShares24.5052wk High2.11P/B13.26BFloat Cap12.7752wk Low20.97Limit Up685.34MShs Float52.71Historical High17.15Limit Down3.36%Amplitude6.72Historical Low0.38Dividend TTM19.41Avg Price26.02KlotAsk1.96%Div YieldTTM100Lot Size28.40KlotBid
Chengdu Kanghong Pharmaceutical Group Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Current assets | ||||||||||
| Money funds | 31.59%3.33B | 0.61%3B | 45.62%3.11B | 31.15%4.7B | 60.99%2.53B | 72.81%2.98B | 11.66%2.14B | 22.00%3.59B | -23.15%1.57B | -31.35%1.73B |
| Transactional financial assets | 12.69%2.22B | 98.69%2.12B | 15.67%1.95B | ---- | 22.21%1.97B | -14.54%1.07B | 23.04%1.69B | -50.00%100M | 40.16%1.61B | 144.32%1.25B |
| Notes receivable and accounts receivable | -6.23%174.62M | 17.26%217.37M | -24.34%170.17M | -0.17%160.41M | -10.44%186.22M | -23.19%185.37M | 0.59%224.92M | -21.48%160.69M | -33.59%207.94M | -19.11%241.34M |
| -Notes receivable | -80.45%532.08K | ---- | ---- | ---- | -87.03%2.72M | -88.03%3.02M | -77.45%5.61M | -48.39%11.07M | 21.38%20.99M | 96.87%25.21M |
| -Accounts receivable | -5.13%174.09M | 19.20%217.37M | -22.40%170.17M | 7.21%160.41M | -1.85%183.5M | -15.63%182.36M | 10.37%219.31M | -18.32%149.62M | -36.80%186.95M | -24.31%216.13M |
| Other receivables (including interest and dividends) | 61.52%16.53M | 71.96%12.18M | -1.40%18.59M | -35.87%7.05M | -43.78%10.23M | -27.72%7.09M | 13.73%18.85M | 685.15%10.99M | 80.60%18.2M | 513.18%9.8M |
| -Other receivable | ---- | 71.96%12.18M | ---- | ---- | ---- | -27.72%7.09M | ---- | 685.15%10.99M | ---- | 513.18%9.8M |
| Advance payment | 28.17%41.59M | -6.77%25.53M | -45.20%18.68M | -56.37%10.48M | -15.68%32.45M | -10.36%27.39M | 42.37%34.09M | 52.28%24.02M | 68.60%38.48M | 105.60%30.56M |
| Inventories | 7.25%404.42M | 14.00%417.32M | 17.16%401.55M | 21.95%403.61M | 22.05%377.07M | 24.75%366.07M | 21.31%342.73M | 11.95%330.96M | 15.07%308.95M | 23.29%293.45M |
| Other current assets | 32.17%21.05M | -4.37%22.75M | 15.71%23.41M | 28.24%21.92M | 26.56%15.93M | -5.72%23.79M | -55.31%20.24M | -59.60%17.09M | -64.34%12.58M | -52.54%25.23M |
| Total current assets | 21.19%6.2B | 24.84%5.81B | 27.57%5.7B | 25.45%5.31B | 35.86%5.12B | 30.33%4.66B | 15.16%4.47B | 14.34%4.23B | -1.94%3.77B | -1.54%3.57B |
| Non Current assets | ||||||||||
| Long-term equity investment | -0.92%16.58M | -0.55%16.67M | -0.87%16.72M | -1.22%16.78M | -3.33%16.73M | -4.17%16.76M | -4.04%16.87M | -4.22%16.98M | -3.63%17.31M | -3.21%17.49M |
| Fixed assets | ---- | 1.56%2.27B | ---- | ---- | ---- | 79.87%2.23B | ---- | 61.62%2.06B | ---- | 7.67%1.24B |
| Constru in process | ---- | -67.03%75.98M | ---- | ---- | ---- | -78.38%230.48M | ---- | -41.15%475.88M | ---- | 39.90%1.07B |
| Productive biological assets | 11.80%5.43M | 5.34%5.89M | -50.61%4.07M | -47.13%4.55M | -39.42%4.86M | -33.73%5.59M | 55.85%8.25M | 75.99%8.61M | 137.97%8.02M | 341.79%8.44M |
| Intangible assets | -8.42%293.6M | -6.57%301.32M | -4.02%309.15M | -4.33%316.8M | -3.00%320.61M | -3.42%322.53M | 18.76%322.09M | 19.02%331.14M | 18.24%330.53M | 18.25%333.96M |
| Development expenditure | 28.29%106.21M | 26.82%94.48M | 39.89%93.52M | 48.67%92.14M | 92.97%82.79M | 160.68%74.5M | -21.86%66.85M | -15.81%61.98M | -31.39%42.9M | -52.52%28.58M |
| Long deferred expense | -24.60%4.81M | -20.48%5.87M | -20.22%6.18M | -15.25%7.19M | -26.96%6.38M | -24.62%7.38M | -22.78%7.75M | -23.20%8.48M | 639.56%8.74M | 469.39%9.79M |
| Deferred tax assets | -37.16%242.66M | -36.83%271.94M | -33.07%312.28M | -26.37%358.08M | -21.61%386.19M | -15.53%430.48M | -11.86%466.55M | -10.88%486.31M | 1.79%492.63M | 7.02%509.62M |
| Usufruct assets | 75.96%5.94M | 44.30%5.57M | -52.34%1.99M | -54.94%2.12M | -35.87%3.38M | -32.56%3.86M | -33.62%4.17M | -31.36%4.71M | 0.76%5.26M | 34.88%5.72M |
| Other non current assets | -19.69%22.14M | -53.55%16.77M | -28.90%23.75M | -35.11%22.01M | -95.45%27.57M | -93.03%36.09M | -87.84%33.41M | -85.49%33.93M | 130.15%605.76M | 112.16%517.68M |
| Total non current assets | -8.07%3.01B | -8.88%3.06B | -8.60%3.14B | -7.66%3.22B | -14.84%3.27B | -10.13%3.36B | 0.59%3.43B | 7.19%3.49B | 15.66%3.84B | 16.16%3.74B |
| Total assets | 9.78%9.21B | 10.71%8.88B | 11.85%8.83B | 10.48%8.53B | 10.25%8.39B | 9.64%8.02B | 8.34%7.9B | 10.99%7.72B | 6.22%7.61B | 6.78%7.31B |
| Liabilities | ||||||||||
| Current liabilities | ||||||||||
| Notes payable and accounts payable | -19.15%243.74M | -21.68%266.52M | -24.23%255.97M | -16.00%344.03M | -0.54%301.45M | 20.38%340.28M | -6.00%337.83M | 19.35%409.54M | 26.76%303.09M | 17.33%282.68M |
| -Accounts payable | -19.15%243.74M | -21.68%266.52M | -24.23%255.97M | -16.00%344.03M | -0.54%301.45M | 20.38%340.28M | -6.00%337.83M | 19.35%409.54M | 26.76%303.09M | 17.33%282.68M |
| Contract liabilities | -44.18%3.82M | 4.68%6.53M | 79.56%6.67M | -44.21%5.1M | 37.21%6.84M | -3.03%6.23M | -57.81%3.71M | 8.94%9.14M | -19.70%4.98M | -39.28%6.43M |
| Advance receipts | 21.23%4.85M | 63.89%4.35M | 161.18%16.27M | 92.91%3.88M | 25.16%4M | -65.38%2.65M | -81.93%6.23M | -58.27%2.01M | 21.36%3.2M | 126.33%7.67M |
| Salaries payable | 6.65%24.45M | 4.17%41.8M | -1.13%38.68M | 30.73%133.98M | 5.23%22.93M | 80.73%40.13M | 74.18%39.13M | 4.37%102.49M | -3.90%21.79M | -2.98%22.2M |
| Taxs payable | -7.71%51.2M | 6.44%50.06M | -29.47%55.22M | -12.45%35.95M | 2.33%55.47M | -26.46%47.03M | 16.23%78.29M | 10.12%41.06M | -11.27%54.21M | 0.78%63.95M |
| Other payable (including interest and dividends) | 25.45%336.64M | 63.28%240.75M | 65.48%181.44M | -2.24%64.36M | 16.82%268.34M | 1.52%147.44M | -9.97%109.64M | -7.67%65.83M | -3.59%229.7M | 6.28%145.24M |
| -Other payable | ---- | 63.28%240.75M | ---- | ---- | ---- | 1.52%147.44M | ---- | -7.67%65.83M | ---- | 6.28%145.24M |
| Non current liabilities due within one year | 84.31%2.41M | 41.27%2.38M | -11.33%407.56K | -66.72%531.82K | -26.42%1.31M | -12.28%1.68M | -39.70%459.63K | -37.77%1.6M | --1.77M | --1.92M |
| Other current liabilities | 20.79%68.4M | 17.25%57.76M | 26.89%39.83M | 7.44%66.59M | -22.01%56.63M | -23.38%49.26M | -63.38%31.39M | -39.04%61.98M | 11.21%72.6M | 16.56%64.29M |
| Total current liabilities | 2.58%735.49M | 5.58%670.14M | -2.01%594.5M | -5.66%654.43M | 3.71%716.96M | 6.78%634.71M | -13.43%606.68M | 3.94%693.66M | 8.83%691.35M | 11.50%594.39M |
| Current liabilities | ||||||||||
| Long term account payable | ---- | --0 | ---- | ---- | ---- | --0 | ---- | --0 | ---- | --0 |
| Specific account payable | ---- | -71.22%17.66M | ---- | ---- | ---- | -48.23%61.37M | ---- | -41.66%88.51M | ---- | -35.65%118.54M |
| Deferred tax liabilities | 60.67%11.05M | 66.21%10.44M | 51.62%8.58M | 54.56%7.94M | 276.06%6.88M | 229.59%6.28M | 185.23%5.66M | 149.43%5.14M | -14.42%1.83M | -13.92%1.91M |
| Long term deferred income | -19.62%17.7M | -19.25%18.12M | -18.90%18.54M | -25.63%17.31M | 3.94%22.02M | -0.46%22.44M | -4.87%22.86M | -8.77%23.27M | -42.91%21.19M | -43.37%22.54M |
| Lease liabilities | 134.39%3.88M | 79.55%3.24M | -63.40%1.52M | -54.73%1.48M | -49.08%1.65M | -43.10%1.8M | -8.29%4.15M | -26.27%3.27M | -33.98%3.25M | -15.73%3.17M |
| Total non current liabilities | -46.41%42.76M | -46.17%49.46M | -47.97%55.48M | -47.31%63.33M | -38.90%79.79M | -37.12%91.9M | -35.24%106.64M | -34.58%120.19M | -38.16%130.58M | -36.56%146.16M |
| Total liabilities | -2.32%778.25M | -0.96%719.61M | -8.88%649.98M | -11.81%717.76M | -3.06%796.75M | -1.88%726.61M | -17.58%713.32M | -4.37%813.85M | -2.89%821.93M | -3.00%740.55M |
| Shareholders equity | ||||||||||
| Paid-in capital | 0.03%919.78M | 0.03%919.76M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M | 0.00%919.46M |
| Capital reserve funds | 0.43%2B | 0.04%2B | -0.22%1.99B | -0.22%1.99B | -0.23%1.99B | 0.26%2B | 0.30%1.99B | 0.38%1.99B | 0.43%1.99B | 0.46%1.99B |
| Surplus reserve funds | 5.24%515.32M | 5.78%515.32M | 5.95%515.32M | 7.16%515.32M | 3.13%489.68M | 3.15%487.16M | 3.73%486.36M | 4.54%480.87M | 3.07%474.81M | 3.81%472.27M |
| Retained profit | 19.54%5.01B | 21.44%4.72B | 25.70%4.75B | 24.86%4.38B | 24.15%4.19B | 23.19%3.89B | 25.53%3.78B | 28.77%3.51B | 14.09%3.37B | 15.70%3.16B |
| Other composite income | -18.66%-1.49M | -65.08%-1.81M | -41.95%-1.93M | -27.74%-1.34M | -96.30%-1.26M | 6.54%-1.1M | -29.45%-1.36M | -26.53%-1.05M | 21.52%-639.45K | -73.78%-1.17M |
| Shareholders equity without minority interests | 11.24%8.44B | 11.83%8.15B | 13.87%8.18B | 13.07%7.8B | 12.20%7.58B | 11.50%7.29B | 12.40%7.18B | 13.33%6.9B | 6.95%6.76B | 7.47%6.54B |
| Minority interests | -107.54%-934.11K | 493.27%2.2M | 98.93%5.84M | 55.52%7.89M | -60.15%12.39M | -101.72%-560.35K | -91.63%2.94M | -66.71%5.07M | --31.09M | --32.64M |
| Total shareholder equity | 11.05%8.43B | 11.87%8.16B | 13.91%8.18B | 13.10%7.81B | 11.86%7.6B | 10.94%7.29B | 11.83%7.18B | 13.13%6.91B | 7.45%6.79B | 8.01%6.57B |
| Total liabilityies and equity | 9.78%9.21B | 10.71%8.88B | 11.85%8.83B | 10.48%8.53B | 10.25%8.39B | 9.64%8.02B | 8.34%7.9B | 10.99%7.72B | 6.22%7.61B | 6.78%7.31B |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Shinaga Zhonghe Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CN
Overall
Symbol
Price
% Chg
No Data
